Report cover image

Respiratory Syncytial Virus (RSV) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

Publisher GlobalData
Published Mar 31, 2023
Length 69 Pages
SKU # GBDT17909484

Description

Respiratory Syncytial Virus (RSV) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape


Summary

This reports provides a data-driven overview of the current and future competitive landscape in RSV therapeutics.
  • There will be 20,901,943 diagnosed seropositive prevalent cases of RSV across the 8MM in 2023.
  • Currently, there are only three marketed drugs for RSV: two monoclonal antibodies (palivizumab and nirsevimab) and one antiviral drug (ribavirin).
  • R&D activity within the RSV space is significant, with 10 pipeline products in late-stage clinical development.
  • Commercial sponsors currently dominate the RSV clinical development space, with the US, Spain, and Australia emerging as key countries for conducting Phase III trials in RSV.
  • Three licensing agreements, one acquisition deal, and two partnerships were implemented among companies developing RSV assets in the past 12 months.
Scope

GlobalData’s Respiratory Syncytial Virus (RSV) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -
  • Disease Landscape
  • Disease Overview
  • Epidemiology Overview
  • Treatment Overview
  • Marketed Products Assessment
  • Breakdown by Mechanism of Action, Molecule Type, Route of Administration
  • Product Profiles with Sales Forecast
  • Pricing and Reimbursement Assessment
  • Annual Therapy Cost
  • Time to Pricing and Time to Reimbursement
  • Pipeline Assessment
  • Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
  • Product Profiles with Sales Forecast
  • Late-to-mid-stage Pipeline Drugs
  • Phase Transition Success Rate and Likelihood of Approval
  • Clinical Trials Assessment
  • Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
  • Enrolment Analytics, Site Analytics, Feasibility Analysis
  • Deals Landscape
  • Mergers, Acquisitions, and Strategic Alliances by Region
  • Overview of Recent Deals
  • Commercial Assessment
  • Key Market Players
  • Future Market Catalysts
Reasons to Buy
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the RSV market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global RSV market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

69 Pages
  • Key Findings
    • Disease Etiology
    • Epidemiology Overview: Diagnosed Seropositive Prevalent Cases of RSV in 2023 and 2028
    • Treatment Guidelines
    • Marketed Drugs - Leading Marketed Drugs in RSV
    • Marketed Drugs - Overview by Mechanism of Action
    • Marketed Drugs - Overview by Route of Administration
    • Marketed Drugs - Overview by Molecule Type
    • Marketed Drug Profile - AstraZeneca’s Beyfortus
    • Marketed Drug Profile - AbbVie’s Synagis
    • Marketed Drugs - Average Therapy Cost
    • Pipeline Drugs Overview - Pre-registration and Phase III Pipeline Drugs in RSV
    • Pipeline Drugs - Overview by Development Stage
    • Pipeline Drugs - Overview by Mechanism of Action
    • Pipeline Drugs - Overview by Route of Administration
    • Pipeline Drugs - Overview by Molecule Type
    • Pipeline Drugs - Drug-Specific Phase Transition Success Rate and Likelihood of Approval in RSV
    • Pipeline Drugs - Phase Transition Success Rate and Likelihood of Approval in Respiratory Disorders
    • Clinical Trials in RSV - Historical Overview
    • Clinical Trials in RSV - Overview by Phase
    • Clinical Trials in RSV - Overview by Status
    • Clinical Trials in RSV - Overview by Phase for Ongoing and Planned Trials
    • Clinical Trials in RSV - Trials with a Virtual Component
    • Clinical Trials in RSV - Geographic Overview
    • Clinical Trials in RSV - Single-Country and Multinational Trials by Region
    • Clinical Trials in RSV - Top 20 Sponsors with Breakdown by Phase
    • Clinical Trials in RSV - Top 20 Sponsors with Breakdown by Status
    • Clinical Trials in RSV - Overview by Endpoint Status
    • Clinical Trials in RSV - Overview by Race and Ethnicity
    • Clinical Trials in RSV - Enrollment Data
    • Clinical Trials in RSV - Overview of Sites by Geography
    • Clinical Trials in RSV - Top 10 Countries for Trial Sites
    • Clinical Trials in RSV - Top 20 Sites Globally
    • Clinical Trials - Feasibility Analysis: Geography Overview
    • Clinical Trials - Feasibility Analysis: Benchmark Models for RSV
    • Deals Landscape - Mergers, Acquisitions, and Strategic Alliances in RSV by Region
    • Deals Landscape - Recent Mergers, Acquisitions, and Strategic Alliances in RSV
    • Commercial Assessment - Key Market Players in RSV
    • Future Market Catalysts - Upcoming Market Catalysts in RSV
    • Methodology
    • Methodology - Sales Forecasts
    • Methodology - Pricing and Reimbursement
    • Methodology - Phase Transition Success Rate and Likelihood of Approval Analysis

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us